Bartzatt Ronald, Cirillo Suat L G, Cirillo Jeffrey D
University of Nebraska, College of Arts & Sciences, Chemistry Department, Omaha, Nebraska 68182, USA.
Physiol Chem Phys Med NMR. 2008;40:55-65.
Over one-third of the world's population has been exposed to Mycobacterium tuberculosis (TB). New drug designs are necessitated by the appearance of multi-drug resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB). This work presents four hydrazide compounds that inhibit Mycobacterium tuberculosis growth at potency comparable to isoniazid. The hydrazide drugs A, B, C, and D were synthesized utilizing microwave excitation methodologies. Hydrazide agents are produced from parent carboxyl compounds. All reactions were accomplished in dry conditions. Using suitable molecular scaffolds the final hydrazides possessed the desired properties in Log P, polar surface area, molecular weight, etc. All four hydrazide compounds induced at least 60% inhibition of TB at concentrations at less than 31.5 microgram/mL. Measured as relative survival, all four hydrazide compounds induced greater than 95% death of TB bacteria at concentrations less than 31.5 microgram/mL. Drugs A, B, C, D exhibited zero violations of the Rule of 5, indicating favorable bioavailability. Although isoniazid, A, B, C, and D were determined to have a polar surface area less than 70 Angstroms2, the values of Log P (a measurement of lipophilicity) showed a broad range of -1.463 (drug C) to 4.46 (drug A). The numerical values of polar surface area suggests that all drugs would have greater than 50% intestinal absorption. For all drugs the number of amine (-NH) and hydroxyl (-OH) groups remains constant at three, with number of oxygens and nitrogens varying only three to four. ANOSIM (analysis of similarity) indicated that isoniazid, A, B, C, and D are highly similar. Correlation of molecular properties for all five drugs is greater than r = 0.9500. Drugs A, B, C, and D are members of two homologous series of anti-tuberculosis agents. All hydrazides effectively inhibited TB at 31.5 micrograms/mL and lower concentrations.
世界上超过三分之一的人口已接触过结核分枝杆菌(TB)。多重耐药结核病(MDR-TB)和广泛耐药结核病(XDR-TB)的出现使得新型药物设计成为必要。这项工作展示了四种酰肼化合物,它们抑制结核分枝杆菌生长的效力与异烟肼相当。酰肼药物A、B、C和D是利用微波激发方法合成的。酰肼剂由母体羧基化合物产生。所有反应均在干燥条件下完成。使用合适的分子支架,最终的酰肼在脂水分配系数(Log P)、极性表面积、分子量等方面具有所需的性质。所有四种酰肼化合物在浓度低于31.5微克/毫升时对结核杆菌的抑制率至少为60%。以相对存活率衡量,所有四种酰肼化合物在浓度低于31.5微克/毫升时对结核杆菌的致死率大于95%。药物A、B、C、D均未违反“五规则”,表明其具有良好的生物利用度。尽管异烟肼、A、B、C和D的极性表面积小于70埃²,但脂水分配系数(衡量亲脂性的指标)的值显示出较宽的范围,从 -1.463(药物C)到4.46(药物A)。极性表面积的数值表明所有药物的肠道吸收率将大于50%。对于所有药物,胺基(-NH)和羟基(-OH)的数量均恒定为三个,氧原子和氮原子的数量仅在三到四个之间变化。相似性分析(ANOSIM)表明异烟肼、A、B、C和D高度相似。所有五种药物的分子性质相关性大于r = 0.9500。药物A、B、C和D是两个抗结核药物同源系列的成员。所有酰肼在31.5微克/毫升及更低浓度下均能有效抑制结核杆菌。